Your Best Stock
Stocks › ABBV

AbbVie ABBV

US equityMarket cap rank #24
$265.06
−$0.03 (-0.01%)
Market open · Sep 24, 2:00 pm ET
After hours $265.12 +0.02%
Open$265.31
Prev close$265.08
Day range$263.09 – $267.41
Volume1.64M
Market cap$468.38B
P/E (TTM)74.9
Dividend yield2.54%

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$16.99B+10.2% YoY
Operating profit$6.72B+17.6% YoY
Net profit$3.62B+284.3% YoY
Diluted EPS$2.03+290.4% YoY
Free cash flow$3.11B-36.2% YoY
Operating cash flow$3.44B

Revenue, last 8 quarters

$14.5BSep '24$15.1BDec '24$13.3BMar '25$15.4BJun '25$15.8BSep '25$16.6BDec '25$15.0BMar '26$17.0BJun '26

Net profit, last 8 quarters

$1.6BSep '24$-23.0MDec '24$1.3BMar '25$941.0MJun '25$188.0MSep '25$1.8BDec '25$697.0MMar '26$3.6BJun '26

Diluted EPS by quarter

0.88Sep '24-0.02Dec '240.72Mar '250.52Jun '250.10Sep '251.02Dec '250.39Mar '262.03Jun '26

Free cash flow by quarter

$5.2BSep '24$6.8BDec '24$1.4BMar '25$4.9BJun '25$6.6BSep '25$4.9BDec '25$3.6BMar '26$3.1BJun '26

Annual revenue

$45.8BFY20$56.2BFY21$58.1BFY22$54.3BFY23$56.3BFY24$61.2BFY25

Profitability & balance sheet

Gross margin71.5%
Operating margin33.9%
Net margin9.7%
Return on assets4.6%
Current ratio0.81
Liabilities / assets104.4%
Cash & investments$6.57B
Total debt$70.82B
Net cash (debt)-$64.25B
Free cash flow / sales28.3%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • SKYRIZI$5.51B 32.4%
  • Other$2.95B 17.4%
  • RINVOQ$2.53B 14.9%
  • All other$1.11B 6.5%
  • Vraylar$1.07B 6.3%
  • Botox Therapeutic$1.04B 6.1%
  • VENCLEXTA$771.00M 4.5%
  • HUMIRA$756.00M 4.4%
  • Botox Cosmetic$728.00M 4.3%
  • IMBRUVICA$532.00M 3.1%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $16.99B $15.00B $61.16B $16.62B $15.78B
Total Operating Revenue $16.99B $15.00B $61.16B $16.62B $15.78B
Cost of Revenue $4.29B $4.22B $18.20B $4.55B $5.30B
Gross Profit $12.70B $10.78B $42.96B $12.07B $10.47B
Operating Expense $5.98B $6.05B $22.87B $6.26B $5.89B
Selling and Admin Expenses $3.63B $3.58B $14.01B $3.90B $3.57B
Research & Development $2.34B $2.47B $9.10B $2.58B $2.32B
Operating Profit $6.72B $4.73B $20.09B $5.81B $4.58B
Net Non-Operating Interest Income (Expense) -$679.00M -$645.00M -$2.63B -$655.00M -$667.00M
Non-Operating Interest Income $67.00M $72.00M $266.00M $59.00M $72.00M
Non-Operating Interest Expense $746.00M $717.00M $2.89B $714.00M $739.00M
Other Income (Expense) -$1.77B -$3.05B -$10.87B -$2.49B -$3.20B
Special Income (Charges) -$291.00M -$744.00M -$5.02B -$1.27B -$2.68B
-Less:Other Special Charges $291.00M $744.00M $5.02B $1.27B $2.68B
Other Non-Operating Income (Expenses) -$1.48B -$2.31B -$5.79B -$1.21B -$503.00M
Pretax Profit $4.28B $1.04B $6.60B $2.67B $714.00M
Tax $662.00M $342.00M $2.36B $853.00M $526.00M
Net Profit $3.62B $697.00M $4.23B $1.82B $188.00M
Profit from Continuing Operations $3.62B $697.00M $4.23B $1.82B $188.00M
Minority Interests $3.00M $2.00M $7.00M -$1.00M $2.00M
Net Income to Parent Company $3.61B $695.00M $4.23B $1.82B $186.00M
Other Preferred Stock Dividends $12.00M $10.00M $40.00M $10.00M $10.00M
Net Income to Common Stockholders $3.60B $685.00M $4.19B $1.81B $176.00M
Basic EPS $2.04 $0.39 $2.37 $1.03 $0.10
Diluted EPS $2.03 $0.39 $2.37 $1.02 $0.10
Dividend Per Share $1.73 $1.73 $6.56 $1.64 $1.64
Other Operating Expenses – – -$241.00M -$217.00M –
Gain on Sale of Security – – -$58.00M -$11.00M -$20.00M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $135.12B $136.46B $133.96B $133.96B $133.90B
Total Current Assets $33.67B $33.53B $29.06B $29.06B $28.54B
Cash and Cash Equivalents & Short-Term Investments $6.57B $9.39B $5.26B $5.26B $5.67B
-Cash and Cash Equivalents $6.57B $9.39B $5.23B $5.23B $5.63B
Receivables $13.82B $12.48B $12.59B $12.59B $12.77B
-Accounts Receivable $13.82B $12.48B $12.59B $12.59B $12.77B
Inventory $5.13B $5.05B $4.95B $4.95B $4.94B
Other Current Assets $8.15B $6.61B $6.27B $6.27B $5.16B
Total Non-Current Assets $101.45B $102.93B $104.90B $104.90B $105.36B
Net PPE $5.80B $5.69B $5.63B $5.63B $5.48B
-Gross PPE $13.96B $13.73B $13.53B $13.53B $13.23B
-Accumulated Depreciation -$8.16B -$8.04B -$7.90B -$7.90B -$7.75B
Investments and Advances $266.00M $268.00M $268.00M $268.00M $291.00M
Goodwill and Other Intangible Assets $84.66B $86.44B $88.28B $88.28B $89.94B
-Goodwill $35.52B $35.57B $35.64B $35.64B $35.63B
-Other Intangible Assets $49.14B $50.87B $52.64B $52.64B $54.32B
Other Non-Current Assets $10.73B $10.54B $10.72B $10.72B $9.64B
Total Liabilities $141.00B $143.08B $137.19B $137.19B $136.50B
Total Current Liabilities $41.64B $42.10B $43.29B $43.29B $39.39B
Short-Term Debt and Capital Lease Obligation $8.34B $8.33B $8.56B $8.56B $5.77B
-Current Debt $8.34B $8.33B $8.56B $8.56B $5.77B
Total Non-Current Liabilities $99.36B $100.98B $93.90B $93.90B $97.11B
Long Term Debt and Capital Lease Obligation $62.48B $64.53B $58.94B $58.94B $62.97B
-Long Term Debt $62.48B $64.53B $58.94B $58.94B $62.97B
Non-Current Deferred Liabilities $2.28B $2.33B $2.39B $2.39B $2.48B
Other Non-Current Liabilities $34.60B $34.11B $30.80B $30.80B $31.66B
Total Equity -$5.89B -$6.61B -$3.23B -$3.23B -$2.60B
Stockholders' Equity -$5.94B -$6.66B -$3.27B -$3.27B -$2.64B
Capital Stock $18.00M $18.00M $18.00M $18.00M $18.00M
-Common Stock $18.00M $18.00M $18.00M $18.00M $18.00M
Additional Paid-In Capital $23.16B $22.96B $22.50B $22.50B $22.29B
Retained Earnings -$17.33B -$17.87B -$15.49B -$15.49B -$14.23B
Less: Treasury Stock $10.62B $10.61B $9.15B $9.15B $9.14B
Gains/Losses Not Affecting Retained Earnings -$1.16B -$1.15B -$1.14B -$1.14B -$1.57B
Minority Interests $47.00M $44.00M $42.00M $42.00M $43.00M
-Short Term Investments – – $28.00M $28.00M $42.00M
Payables – – $6.69B $6.69B –
-Accounts Payable – – $3.59B $3.59B –
-Dividends Payable – – $3.10B $3.10B –
Current Accrued Expenses – – $28.04B $28.04B –
Long Term Accounts Payable and Other Payables – – $364.00M $364.00M –
Employee Benefits – – $1.41B $1.41B –

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $3.44B $3.83B $19.03B $5.22B $7.02B
Net cash flow from continuing operations $3.44B $3.83B $19.03B $5.22B $7.02B
Net Income from Continuing Operations $3.62B $697.00M $4.23B $1.82B $188.00M
Depreciation & Depletion & Amortization $1.88B $1.94B $8.14B $1.99B $2.06B
Deferred Tax -$195.00M $137.00M -$492.00M -$385.00M $193.00M
Other Non-Cash Items $601.00M $2.54B $8.64B $1.98B $2.59B
Change in Working Capital -$2.72B -$1.92B -$2.36B -$473.00M $1.25B
-Change in Receivables -$1.37B $87.00M -$1.49B $162.00M -$156.00M
-Change in Inventory -$143.00M -$184.00M -$234.00M -$25.00M $2.00M
-Change in Prepaid Assets -$188.00M -$150.00M -$827.00M -$658.00M $88.00M
-Change in Payables and Accrued Expense $1.20B -$1.59B $951.00M -$598.00M $1.73B
-Change In Other Working Capital -$2.22B -$81.00M -$762.00M $646.00M -$411.00M
Net cash flow from investing -$1.20B -$574.00M -$6.64B -$1.46B -$3.26B
Net Cash Flow from Continuing Investing Activities -$1.20B -$574.00M -$6.64B -$1.46B -$3.26B
Net PPE Purchase and Sale -$322.00M -$265.00M -$1.21B -$329.00M -$381.00M
Net Business Purchase and Sale -$824.00M -$266.00M -$5.44B -$1.16B -$2.80B
Net Other Investing Changes -$51.00M -$43.00M -$29.00M -$1.00M -$94.00M
Financing Cash Flow -$5.05B $919.00M -$12.72B -$4.17B -$4.59B
Net Cash Flow from Continuing Financing Activities -$5.05B $919.00M -$12.72B -$4.17B -$4.59B
Net Issuance Payments Of Debt -$2.00B $5.49B -$304.00M -$1.30B -$1.78B
Net Common Stock Issuance -$9.00M -$1.49B -$980.00M -$3.00M -$4.00M
Cash Dividends Paid -$3.07B -$3.09B -$11.66B -$2.91B -$2.91B
Net Other Financing Charges $25.00M $2.00M $45.00M -$1.00M -$24.00M
Ending Cash Balance $6.57B $9.39B $5.23B $5.23B $5.63B
Net Change in Cash -$2.82B $4.17B -$337.00M -$411.00M -$830.00M
Beginning Cash Balance $9.39B $5.23B $5.52B $5.63B $6.47B
Effect of Exchange Rate Changes -$7.00M -$12.00M $42.00M $11.00M -$8.00M
Free Cash Flow $3.11B $3.56B $17.82B $4.89B $6.64B
Net Investment Purchase and Sale – – $41.00M $28.00M -$4.00M
Proceeds from Stock Option Exercised – – $172.00M $48.00M $63.00M
Scroll to Top